Auron Therapeutics begins patient dosing in phase 1 trial of AUTX-703 in advanced hematologic malignancies: Newton, Massachusetts Monday, June 2, 2025, 16:00 Hrs [IST] Auron Thera ...

The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel ...

A novel triple reuptake inhibitor is efficacious and ‘clinically meaningful’ for adult attention-deficit/hyperactivity ...

The findings suggest that "the heightened focus on alternative endpoints, now representing the most common primary endpoint, ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

UC Davis Comprehensive Cancer Center is testing a drug called niraparib (ZEJULA), given before prostate cancer surgery.

The trial focused on a drug called Duavee, a combination of conjugated estrogens and bazedoxifene, which is already approved ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...